Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 4/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.66 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
| ▸ | WEE1 | P30291 | 10/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.56 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583941 | 0.90 | SRC (0.63) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL4422225 | 0.84 | CDK4 (0.52) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL14573081 | 0.84 | WEE1 (0.56) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL5583949 | 0.82 | SRC (0.62) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL5583960 | 0.81 | FGFR1 (0.48) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL29037749 | 0.80 | ALK (0.69) | SRCFGFR1SLC2A1MAPK14LCK | |
| SCHEMBL5583903 | 0.78 | FGFR1 (0.55) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL5583802 | 0.77 | ABL1 (0.61) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL2252553 | 0.77 | FGFR1 (0.81) | SRCFGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL5583794 | 0.76 | EGFR (0.50) | SRCFGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007529451-A | — | — | 2007-10-25 | — | — | JP | claimed |
| US-7189732-B2 | Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | claimed |
| EP-1727819-A1 | NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | claimed |
| US-20060014765-A1 | Dichloro-phenyl derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-19 | — | — | US | claimed |
| WO-2005090344-A1 | NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-7189732-B2 | Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1727819-A1 | NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | disclosed |
| US-20060014765-A1 | Dichloro-phenyl derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005090344-A1 | NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | SRC 1484/4885FGFR1 482/4885FGFR4 1521/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | SRC 1586/4885FGFR1 358/4885FGFR4 1253/4885 |
| US-20060014765-A1 | Dichloro-phenyl derivatives | SRC, ABL1, LCK | SRC 1/4885FGFR1 145/4885FGFR4 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.